Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

• Hoofdauteurs: April Armstrong (Auteur), Alvaro González-Cantero (Auteur), Saakshi Khattri (Auteur), Guilherme Muzy (Auteur), William N. Malatestinic (Auteur), Anastasia Lampropoulou (Auteur), Meghan Feely (Auteur), Sophia Kyoungah See (Auteur), Can Mert (Auteur), Andrew Blauvelt (Auteur)
• Formaat: Boek
• Gepubliceerd in: Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Introduction The National Psoriasis Foundation (NPF) recommends evaluating patient response to treatment at week 12, with a target response of ≤ 1% body surface area (BSA) affected by plaque psoriasis and an acceptable response of BSA ≤ 3% or ≥ 75% improvement. This post hoc analysis compar...